1. Cell Cycle/DNA Damage
    NF-κB
  2. PPAR

Pioglitazone hydrochloride (Synonyms: U 72107A; AD 4833)

Cat. No.: HY-14601 Purity: 99.53%
Data Sheet SDS Handling Instructions

Pioglitazone hydrochloride is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

For research use only. We do not sell to patients.
Pioglitazone hydrochloride Chemical Structure

Pioglitazone hydrochloride Chemical Structure

CAS No. : 112529-15-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
100 mg $50 In-stock
500 mg $120 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Pioglitazone hydrochloride:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Pioglitazone hydrochloride is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

IC50 & Target

EC50: 0.93 μM (human PPARγ), 0.99 μM (mouse PPARγ)[1]

In Vitro

AGEs-induced beta cell necrosis is completely abrogated by adding Pioglitazone to the AGEs culture medium. Furthermore Pioglitazone completely prevented any AGEs-induced increment in caspase-3 activation, thereby restoring caspase-3 activity to the same levels as the control cells. As expected AG is able to counteract AGEs-induced impaired viability[2].

In Vivo

The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are significantly reduced to a similar degree after 30 mg/kg Pioglitazone. Moreover, the expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are decreased after 30 mg/kg Pioglitazone. Thus, Pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle[3]. Pioglitazone (10 mg/kg per d) treatment significantly attenuates the loss of body weight (BW) and cardiac hypertrophy. Pioglitazone treatment significantly reduces the elevated serum glucose levels and markedly improved the associated dyslipidemia. Furthermore, there is a slight but significant increase in serum creatinine level in D rats over their N controls (P <0.05). However, a marked renal dysfunction is observed in diabetic nephropathic (DN) group (P<0.05). Moreover, DN rats exhibits the highest serum activity of CK-MB, relative to both N and D rats (P<0.05). Pioglitazone is able to decrease the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB)[4].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00494559 Korea University Anam Hospital Diabetes Mellitus|Coronary Artery Stenosis July 2007 Phase 4
NCT03080480 Children's Hospital of Fudan University Chronic Granulomatous Disease September 1, 2017 Phase 1|Phase 2
NCT01090752 University Hospital, Geneva|University of Lausanne Hospitals Diabetes|Hypertension October 2005 Phase 4
NCT02687425 Meng Li|Tongji Hospital Leukemia, Myelogenous, Chronic, BCR-ABL Positive February 2016 Phase 2
NCT00671515 Joseph Calabrese, MD|Takeda Pharmaceuticals North America, Inc.|University Hospitals Cleveland Medical Center Depressive Disorder, Major|Metabolic Syndrome X April 2008 Phase 2
NCT02697617 Indiana University Polycystic Kidney Disease October 2015 Phase 2
NCT00719381 Paul Beringer|University of Southern California Cystic Fibrosis January 2008 Phase 1
NCT01151670 Wake Forest University Health Sciences Brain Neoplasms, Malignant|Brain Neoplasms, Benign|Malignant Meningioma|Glioblastoma Multiforme|Anaplastic Astrocytoma August 2010 Phase 1
NCT01352182 Children's Hospital Medical Center, Cincinnati Severe Sepsis|Septic Shock October 2011 Phase 1|Phase 2
NCT01637935 Takeda|Kaiser Permanente|Department of Epidemiology at University of Pennsylvania Diabetes|Bladder Cancer July 2004
NCT00811681 Assistance Publique - Hôpitaux de Paris Friedreich's Ataxia December 2008 Phase 3
NCT01931566 Takeda|Zinfandel Pharmaceuticals Inc. Mild Cognitive Impairment Due to Alzheimer's Disease August 2013 Phase 3
NCT01068444 Kaohsiung Medical University Chung-Ho Memorial Hospital Hepatitis April 2009 Phase 2
NCT02958956 Takeda Diabetes Mellitus, Type 2, Cancer January 1997
NCT01935804 King Abdulaziz University Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders January 2009 Phase 2
NCT00835120 University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|Takeda Pharmaceuticals North America, Inc. Metabolic Syndrome|Bipolar Depression|Insulin Resistance March 2009 Phase 4
NCT00845182 The University of Texas Health Science Center at San Antonio Type 2 Diabetes|Healthy|Impaired Glucose Tolerance June 2007 Phase 4
NCT01972724 Takeda Type II Diabetes Mellitus January 2014 Phase 4
NCT01882907 Pusan National University Hospital Type 2 Diabetes December 2009 Phase 4
NCT02133625 Dana-Farber Cancer Institute Advanced Solid Tumor|Metastatic Solid Tumor August 2011 Phase 1
NCT01001013 LG Life Sciences Healthy February 2009 Phase 1
NCT00855010 University of Texas Southwestern Medical Center|National Institutes of Health (NIH) Obesity|Type 2 Diabetes February 2009
NCT01258322 Huashan Hospital|Baxter Healthcare Corporation Peritoneal Dialysis|Pioglitazone|Hypertriglyceridemia|Insulin Resistance|Inflammation January 2008
NCT00861341 University of Rochester Diabetes|Platelet Function|Healthy December 2008 Phase 2
NCT01223196 The University of Texas Health Science Center at San Antonio Type 2 Diabetes August 2009 Phase 4
NCT01186250 Stanford University Cardiac Allograft Vasculopathy July 2010 Phase 2
NCT02284906 Takeda Mild Cognitive Impairment Due to Alzheimer's Disease November 17, 2014 Phase 3
NCT03060772 Emory University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcoholism August 28, 2017 Phase 2
NCT01935466 Postgraduate Institute of Medical Education and Research Bladder Cancer July 2013
NCT01819402 Kurume University To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging March 2012
NCT00770367 Dana King|Takeda Pharmaceuticals North America, Inc.|Medical University of South Carolina Diabetes October 2008 Phase 4
NCT02730195 Emory University Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive May 2016 Phase 2
NCT00099021 National Cancer Institute (NCI) Head and Neck Cancer|Oral Leukoplakia June 2003 Phase 2
NCT01396564 Coordinación de Investigación en Salud, Mexico Type 2 Diabetes October 2005 Phase 1|Phase 2
NCT02181842 Takeda Type 2 Diabetes Mellitus January 2009
NCT01156597 University of Miami|Takeda Pharmaceuticals North America, Inc. Type 2 Diabetes Mellitus April 2008 Phase 3
NCT01280123 University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Michael J. Fox Foundation for Parkinson's Research Parkinson's Disease March 2011 Phase 2
NCT00782795 University of Michigan|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Chronic Pancreatitis|Insulin Resistance|Normal Stool Fat Levels November 2008 Phase 2
NCT01589445 University of Dhaka|Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders|University of Dundee Type 2 Diabetes Mellitus November 2008 Phase 4
NCT00609856 Skane University Hospital|Medical Research Council|Skane County Council Research & Development Foundation Type 2 Diabetes|Secondary Drug Failure April 2004 Phase 4
NCT00545857 Stony Brook University Type 1 Diabetes Mellitus June 2002 Phase 1
NCT01082120 AstraZeneca Type 2 Diabetes Mellitus February 2010 Phase 1
NCT00676260 Takeda Diabetes Mellitus December 2002 Phase 2
NCT00174993 Takeda|Eli Lilly and Company Diabetes Mellitus May 2001 Phase 3
NCT01195090 Sung-Chen Liu|Mackay Memorial Hospital Type 2 Diabetes October 2009 Phase 4
NCT00708175 Takeda Bone Metabolism May 2008 Phase 4
NCT00672919 Takeda Diabetes Mellitus November 2003 Phase 4
NCT00994682 University of Florida|The University of Texas at San Antonio Nonalcoholic Steatohepatitis|Nonalcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus December 2008 Phase 4
NCT00927290 French National Agency for Research on AIDS and Viral Hepatitis|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Chronic Hepatitis C|Insulin Resistance December 3, 2009 Phase 3
NCT00220961 The University of Texas Health Science Center at San Antonio|University of Texas|Takeda Pharmaceuticals North America, Inc. Impaired Glucose Tolerance|Type 2 Diabetes January 2004 Phase 3
NCT00656864 University of Vermont|Takeda Diabetes Mellitus, Type 2 May 2008 Phase 4
NCT01253928 Centre Hospitalier Universitaire Vaudois ESRD March 2007 Phase 4
NCT02002975 Takeda Type 2 Diabetes Mellitus October 2007
NCT02003014 Takeda Type 2 Diabetes Mellitus February 2009
NCT01456117 Takeda Healthy November 2011 Phase 1
NCT00227110 The University of Texas Health Science Center at San Antonio|National Institutes of Health (NIH)|Takeda Pharmaceuticals North America, Inc. Nonalcoholic Steatohepatitis October 2002 Phase 4
NCT00923949 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Non-Small-Cell Lung Cancer August 2008 Phase 2
NCT01695707 University of Rochester|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Atopic Dermatitis March 2013
NCT00639457 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) HIV Infections|Type 2 Diabetes|Obesity|HIV|AIDS|Cardiovascular Disease|Lipodystrophy January 2005
NCT00138554 Novartis Diabetes Mellitus, Type 2 November 2004 Phase 3
NCT02068508 Takeda Type 2 Diabetes Mellitus July 2009
NCT01395784 New York State Psychiatric Institute|Omeros Corporation Opioid Abuse August 2010 Phase 2
NCT01040819 Baylor College of Medicine Type 2 Diabetes Mellitus February 2010 Phase 4
NCT01341730 The Catholic University of Korea|Jeil Pharmaceutical Co., Ltd. Atherosclerosis|Coronary Artery Disease June 2011 Phase 4
NCT02098746 Takeda Type 2 Diabetes June 2011
NCT00576784 IKFE Institute for Clinical Research and Development Type 2 Diabetes Mellitus|Insulin Resistance April 2005 Phase 4
NCT00681733 Govind Ballabh Pant Hospital Metabolic Parameters and Liver Histology January 2007
NCT01559857 Stanford University|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH) Major Depressive Disorder|Insulin Resistance November 2011 Phase 4
NCT01309854 AstraZeneca Rheumatoid Arthritis|Healthy Volunteers|Pharmacokinetics|Pioglitazone|Drug-drug Interaction|Amount of Pioglitazone in Blood March 2011 Phase 1
NCT01472497 Tottori University Hospital Hypertension|Insulin Resistance April 2007 Phase 4
NCT00951379 National Cancer Institute (NCI) Oral Leukoplakia February 2010 Phase 2
NCT00494312 Takeda Diabetes Mellitus|Liver October 2000 Phase 4
NCT00331487 Takeda|Eli Lilly and Company Diabetes Mellitus September 2000 Phase 3
NCT01947790 Xiang Guang-da|Wuhan General Hospital of Guangzhou Military Command LVM|Type 2 Diabetic Patients With IHD|Endothelial Function September 2013 Phase 4
NCT01990300 Takeda Type 2 Diabetes Mellitus November 28, 2011
NCT02733679 NHS Tayside|University of Dundee Ataxia-Telangiectasia September 2016 Phase 4
NCT00771004 Takeda Oxidative Stress|Coronary Artery Disease|Type 2 Diabetes August 2006 Phase 2
NCT00521820 Takeda Diabetes Mellitus June 2000 Phase 3
NCT01655719 University of Michigan Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene April 2012 Phase 2
NCT01342770 National Cancer Institute (NCI) Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer April 2011 Phase 2
NCT00770640 Takeda Diabetes Mellitus August 2008 Phase 2
NCT00770952 Takeda Diabetes Mellitus December 2006 Phase 3
NCT00402012 Pennington Biomedical Research Center|Takeda Pharmaceuticals North America, Inc. Diabetes Mellitus, Type 2 November 2006 Phase 4
NCT01124656 Takeda Diabetes Mellitus, Type 2 September 2006 Phase 3
NCT01322308 National Heart Institute, Mexico|National Council of Science and Technology, Mexico|Universidad Nacional Autonoma de Mexico Systemic Lupus Erythematosus March 2007 Phase 4
NCT01717040 University Hospitals Cleveland Medical Center|The Depressive and Bipolar Disorder Alternative Treatment Foundation Bipolar Disorder|Insulin Resistance September 2012 Phase 4
NCT00772174 Takeda Diabetes Mellitus January 2007 Phase 3
NCT00690118 University of Ulm Amyotrophic Lateral Sclerosis May 2008 Phase 2
NCT00770575 Takeda Cardiovascular Diseases June 2005 Phase 2
NCT01109030 Tehran University of Medical Sciences Major Depressive Disorder April 2010 Phase 2|Phase 3
NCT00225277 Takeda Diabetes Mellitus July 2003 Phase 3
NCT01184144 University of Wisconsin, Madison Endometriosis August 2010 Phase 2|Phase 3
NCT00376870 University of Rome Tor Vergata Coronary Atherosclerosis|Coronary Restenosis|Diabetes July 2008 Phase 3
NCT00775164 University of Minnesota - Clinical and Translational Science Institute Obesity|Insulin Resistance January 2009 Phase 4
NCT00780234 VA Office of Research and Development Lung Cancer|Endobronchial Dysplasia August 2009 Phase 2
NCT02099838 Huazhong University of Science and Technology|Wuhan Iron and Steel Workers' Hospital|Wuhan Pu-Ai Hospital|Hubei Xinhua Hospital Diabetes Mellitus, Type 2 January 2012 Phase 4
NCT00225264 Takeda Diabetes Mellitus October 2003 Phase 3
NCT01225081 Astellas Pharma Inc Type 2 Diabetes Mellitus October 2010 Phase 3
NCT01301027 University of Utah|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Colorado, Denver End Stage Renal Disease May 2008
NCT02429232 National Taiwan University Hospital Osteoporosis|Diabetes Mellitus October 2015 Phase 4
NCT00485056 Imperial College London Diabetes April 2008 Phase 4
NCT00770497 Takeda Inflammation|Hypertension March 2007 Phase 2
NCT02753803 Dong-A ST Co., Ltd. Type 2 Diabetes May 2016 Phase 1
NCT02303405 Charles Drew University of Medicine and Science Diabetes Mellitus Type 2 With Hyperglycemia November 2014 Phase 2
NCT02027103 Tehran University of Medical Sciences Type 2 Diabetes Mellitus January 2012
NCT00749047 Christchurch Hospital Diabetes Mellitus, Type 2 September 2008 Phase 4
NCT01873001 Janssen Research & Development, LLC Healthy Volunteers May 2013 Phase 1
NCT00231894 Nathan Kline Institute for Psychiatric Research Diabetes|Schizophrenia|Insulin Resistance|Cognitive Impairment May 2005
NCT03125694 Tehran University of Medical Sciences Uncontrolled Type 2 Diabetes Mellitus February 1, 2015 Phase 3
NCT01588470 The University of Texas Health Science Center at San Antonio|Takeda Pharmaceuticals North America, Inc. Type 2 Diabetes|Coronary Heart Disease June 2006 Phase 4
NCT00570622 Medical University of Vienna Cirrhosis|Ascites|Portal Hypertension December 2004 Phase 4
NCT00189163 University of Michigan Chronic Hepatitis C January 2005 Phase 4
NCT00479986 IKFE Institute for Clinical Research and Development|Takeda|Johannes Gutenberg University Mainz|Heidelberg University Type 2 Diabetes Mellitus|Cardiovascular Disease June 2005 Phase 4
NCT00634036 Fernando Holguin|Takeda|University of Vermont|University of Pittsburgh Asthma October 2009 Phase 2
NCT01205282 Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|Anagnostou, Evdokia, M.D. Autism Spectrum Disorders April 2013 Phase 2
NCT00736996 University of Colorado, Denver|National Institute on Aging (NIA) Mild Cognitive Impairment November 2008 Phase 2
NCT00770445 Takeda Diabetes Mellitus May 2008 Phase 4
NCT01963663 Tehran University of Medical Sciences Type 2 Diabetes Mellitus November 2012
NCT01703260 AstraZeneca Nonalcoholic Steatohapatitis June 2013 Phase 2
NCT01088919 Astellas Pharma Inc Healthy|Pharmacokinetics of ASP1941 November 2009 Phase 1
NCT00770835 Takeda Diabetes Mellitus March 2009 Phase 4
NCT00991055 National Cheng-Kung University Hospital Type 2 Diabetes May 2008 Phase 4
NCT00754403 Takeda Diabetes Mellitus July 2005 Phase 4
NCT02426294 Pusan National University Hospital Type 2 Diabetes Mellitus February 2015 Phase 4
NCT00982202 National Institute on Aging (NIA)|Takeda Pharmaceuticals North America, Inc. Alzheimer Disease January 2002 Phase 2
NCT00770653 Takeda Diabetes Mellitus|Dyslipidemias April 2007 Phase 3
NCT00432276 Takeda Diabetes Mellitus January 2007 Phase 3
NCT00395512 Takeda Diabetes Mellitus November 2006 Phase 3
NCT00868140 Virginia Commonwealth University Polycystic Ovary Syndrome February 2009
NCT00926016 Brooke Army Medical Center|The Geneva Foundation Chronic Hepatitis C June 2006
NCT00328393 University of Erlangen-Nürnberg Medical School Hypertension|Diabetes Mellitus Type 2 March 2007 Phase 3
NCT00408850 Baker Heart Research Institute|National Heart Foundation, Australia Metabolic Syndrome November 2008 Phase 3
NCT00742326 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) HIV|Hepatitis C|Liver Disease|Fatty Liver|Steatosis August 2008 Phase 4
NCT00062764 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) Hepatitis June 2003 Phase 2
NCT00376181 Takeda Type 2 Diabetes June 2006 Phase 3
NCT01593371 Tehran University of Medical Sciences Type 2 Diabetes Mellitus July 2011
NCT01799850 East Tennessee State University|Takeda Pharmaceuticals North America, Inc. Diabetes Type 2 March 2002 Phase 4
NCT01838317 University of Texas Southwestern Medical Center Cancer of the Pancreas May 2013 Phase 2
NCT02195791 Taipei Medical University Shuang Ho Hospital Stroke July 2014 Phase 2
NCT00727857 Takeda Diabetes Mellitus June 2007 Phase 3
NCT03117517 Khyber Medical University Peshawar Polycystic Ovarian Syndrome March 20, 2017 Early Phase 1
NCT00521742 Takeda|Takeda Pharmaceuticals North America, Inc. Diabetes Mellitus March 2001 Phase 3
NCT00633282 Xin Gao|Shanghai Jiao Tong University School of Medicine|Shanghai Municipal Science and Technology Commission|Fudan University Nonalcoholic Fatty Liver Disease March 2008 Phase 2
NCT00397631 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus December 19, 2006 Phase 3
NCT01023620 University of Texas Southwestern Medical Center|Takeda Pharmaceuticals North America, Inc. HIV Infections October 2009
NCT01115712 Merck Sharp & Dohme Corp. Healthy|Overweight|Obesity May 2010 Phase 1
NCT00789750 Daiichi Sankyo Inc. Type 2 Diabetes Mellitus April 2009 Phase 3
NCT00507494 Technische Universität Dresden Diabetes Mellitus|Kidney Transplantation|Proteinuria July 2007 Phase 3
NCT02889003 Versailles Hospital Chronic Myeloid Leukemia (CML) October 2016 Phase 2
NCT00919555 Phoenix Neurological Associates, LTD Amyotrophic Lateral Sclerosis June 2008 Phase 1|Phase 2
NCT02222441 Pfizer Healthy October 2014 Phase 1
NCT00545233 Hoffmann-La Roche Hepatitis C, Chronic January 2008 Phase 4
NCT01331967 Korea University Anam Hospital Diabetic Stable Angina|Diabetic Unstable Angina February 2011 Phase 4
NCT00532935 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus January 26, 2008 Phase 3
NCT00286494 Takeda Diabetes Mellitus February 2006 Phase 3
NCT00449553 Takeda|Eli Lilly and Company Diabetes Mellitus June 2001 Phase 4
NCT00328627 Takeda Type 2 Diabetes Mellitus May 2006 Phase 3
NCT00099853 Novartis Pharmaceuticals|Novartis Diabetes Mellitus, Type 2 May 2004 Phase 3
NCT00441272 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) HIV Infections|Hepatic Steatosis|Insulin Resistance February 2007 Phase 2
NCT02942758 University Hospital Regensburg|Anticancer Fund, Belgium|Celgene Acute Myeloid Leukemia April 10, 2017 Phase 2
NCT02183337 Boehringer Ingelheim Healthy February 2007 Phase 1
NCT01106131 Chong Kun Dang Pharmaceutical Type 2 Diabetes Mellitus May 2010 Phase 3
NCT00364988 Shanghai Jiao Tong University School of Medicine Type 2 Diabetes|Diabetic Nephropathy January 2005
NCT02024971 Takeda Type 2 Diabetes Mellitus July 2010
NCT00598013 Yonsei University Kidney Transplantation|Insulin Resistance|Atherosclerosis November 2004
NCT00655863 Takeda Diabetes Mellitus July 2007 Phase 3
NCT00148850 French National Agency for Research on AIDS and Viral Hepatitis|Takeda HIV-Associated Lipodystrophy Syndrome|HIV Infections February 2003 Phase 3
NCT01517165 National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC) Opioid-Related Disorders January 4, 2012 Phase 1
NCT02852486 University of Campinas, Brazil Leukemia, Chronic Myeloid June 2016 Phase 2
NCT02265276 Command Hospital, India Fatty Liver October 2014 Phase 3
NCT00816218 The University of Texas Health Science Center at San Antonio|Takeda Type 2 Diabetes Mellitus March 2003 Phase 4
NCT01276327 Boehringer Ingelheim Healthy January 2011 Phase 1
NCT00825266 Stanford University Hypertension, Pulmonary September 2008 Phase 2
NCT00819325 Queen Elizabeth II Health Sciences Centre|Nova Scotia Health Research Foundation Coronary Artery Disease|Angina Pectoris|Type 2 Diabetes Mellitus|Percutaneous Coronary Intervention August 2002 Phase 4
NCT00649012 Mylan Pharmaceuticals Healthy March 2003 Phase 1
NCT00212004 National Cerebral and Cardiovascular Center Diabetes Mellitus|Myocardial Infarction April 2005
NCT00649558 Mylan Pharmaceuticals Healthy February 2003 Phase 1
NCT02231021 Kun-Ho Yoon|Takeda|The Catholic University of Korea Type 2 Diabetes Mellitus September 2014 Phase 4
NCT00722631 Kurume University Impaired Glucose Tolerance|Type 2 Diabetes Mellitus|Atherosclerosis May 2007
NCT00531882 University Hospitals Cleveland Medical Center Cystic Fibrosis|Anti Inflammatory Non-Steroidal|Neutrophils September 2007
NCT01028391 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus September 1, 2007 Phase 3
NCT02192684 Stanford University Insulin Sensitivity|Obstructive Sleep Apnea September 2010
NCT02371603 GlaxoSmithKline Anaemia February 11, 2015 Phase 1
NCT00013598 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) Fatty Liver|Nonalcoholic Steatohepatitis March 2001 Phase 2
NCT00063622 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Diseases January 2005 Phase 3
NCT00994175 National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Severe, Refractory Asthma|Airway Inflammation|Airflow Obstruction September 23, 2009 Phase 2
NCT02689843 Shiraz University of Medical Sciences Polycystic Ovary Syndrome March 2016 Early Phase 1
NCT00604578 National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Asthma|Airway Inflammation|Airflow Obstruction|Airway Hyperactivity January 4, 2008 Phase 2
NCT02276365 Boehringer Ingelheim Healthy June 2009 Phase 1
NCT00482183 Showa University Coronary Artery Disease|Type 2 Diabetes Mellitus July 2003 Phase 2|Phase 3
NCT00641043 Boehringer Ingelheim Diabetes Mellitus, Type 2 March 2008 Phase 3
NCT00433069 University Hospital, Geneva Chronic Hepatitis C January 2007 Phase 2
NCT00314561 Korea University Anam Hospital Metabolic Syndrome May 2006 Phase 4
NCT00787644 University of Vermont|American Lung Association|University of Pittsburgh Asthma|Obesity January 2009 Phase 2
NCT00159211 Assistance Publique - Hôpitaux de Paris|Laboratoires Takeda Type 2 Diabetes May 2005
NCT01161394 University at Buffalo|Takeda Pharmaceuticals North America, Inc. Inflammation Phase 4
NCT01157975 University of California, San Diego Hepatitis C October 2008 Phase 2
NCT02852083 University Hospital Regensburg|The Anticancer Fund Squamous Cell Lung Cancer|Non-Squamous Cell Lung Cancer|Non-Small Cell Lung Cancer January 2016 Phase 2
NCT02183636 Boehringer Ingelheim Healthy August 2009 Phase 1
NCT00322868 University Hospitals Cleveland Medical Center|Cystic Fibrosis Foundation Therapeutics Cystic Fibrosis April 2006
NCT02342067 Tobira Therapeutics, Inc. Healthy December 2014 Phase 1
NCT00722371 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus September 5, 2008 Phase 3
NCT00827892 The University of Texas Health Science Center, Houston Intracerebral Hemorrhage March 2009 Phase 2
NCT00720577 ev3|FoxHollow Technologies|Merck Sharp & Dohme Corp. Peripheral Arterial Disease December 2005 Early Phase 1
NCT02585765 James J. Peters Veterans Affairs Medical Center Spinal Cord Injury|Pressure Ulcers February 1, 2017 Phase 2
NCT00151710 Radboud University Congenital Adrenal Hyperplasia
NCT02347813 University of Rochester Squamous Cell Carcinoma of the Skin November 2014 Phase 2
NCT00926614 Brooke Army Medical Center Hepatitis c September 2008 Phase 4
NCT00106808 Bristol-Myers Squibb|Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus August 2005 Phase 3
NCT00953498 Centre Hospitalier Universitaire Dijon Type 2 Diabetes October 2007 Phase 4
NCT00399204 Postgraduate Institute of Medical Education and Research|Council of Scientific and Industrial Research, India Type 2 Diabetes January 2006 Phase 4
NCT01431521 Merck Sharp & Dohme Corp. Non-alcoholic Fatty Liver Disease October 1, 2011 Phase 1
NCT00372060 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus August 21, 2006 Phase 3
NCT00665353 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 and Hepatitis C Co-Infection March 2009 Phase 2
NCT01088594 Solvay Pharmaceuticals Type 2 Diabetes Mellitus February 2010 Phase 1
NCT01135394 University of Maryland|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Type 2 Diabetes March 2009
NCT02098733 Takeda Type 2 Diabetes June 2011
NCT00541450 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus January 15, 2008 Phase 3
NCT00763815 Sanofi Diabetes Mellitus Type 2 September 2008 Phase 3
NCT01798940 Torrent Pharmaceuticals Limited Healthy Phase 1
NCT00232362 Texas Tech University Health Sciences Center Type 2 Diabetes Mellitus June 2007 Phase 1
NCT00909597 Hoffmann-La Roche Diabetes Mellitus Type 2 May 2009 Phase 3
NCT00762736 Takeda Diabetes Mellitus July 2004 Phase 2
NCT03011775 Ukrainian Medical Stomatological Academy Adverse Effect|Atherosclerosis, Coronary|Insulin Resistance Syndrome November 2012 Phase 4
NCT00154037 Technische Universität Dresden Healthy Subjects October 2005
NCT02887625 Dr. Muhammad Abdulghani|Hamad Medical Corporation Type 2 Diabetes February 2015
NCT00300365 University of Pennsylvania|Kos Pharmaceuticals Metabolic Syndrome November 2005 Phase 4
NCT00927355 Emory University Osteoblast|Adipocytes|Bone Density|Osteocalcin|Adiponectin|Mesenchymal Stem Cells April 2009
NCT00815399 Second University of Naples Type 2 Diabetes October 2007 Phase 4
NCT00352287 Stanford University Obesity|Metabolic Syndrome|Impaired Glucose Tolerance March 2003 Phase 4
NCT01797666 Torrent Pharmaceuticals Limited Healthy Phase 1
NCT00306826 University of Leipzig|Institut für Gesundheits- und Praxismanagement GmbH Glucose Metabolism Disorders Phase 4
NCT01106690 Janssen Research & Development, LLC Diabetes Mellitus, Type 2 June 2010 Phase 3
NCT01800240 Torrent Pharmaceuticals Limited Healthy Phase 1
NCT01800227 Torrent Pharmaceuticals Limited Healthy Phase 1
NCT00571506 University of Arkansas Diabetes Mellitus, Type 2|Vascular Diseases May 2004 Phase 4
NCT00511108 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus (T2DM) July 11, 2007 Phase 1
NCT01346254 Marcus Saemann|Medical University of Vienna Impaired Glucose Tolerance|Kidney Transplantation December 2009 Phase 2
NCT00631007 InteKrin Therapeutics, Inc. Type 2 Diabetes Mellitus February 2008 Phase 2
NCT00579813 Philip Kern|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky Metabolic Syndrome|Insulin Resistance|Prediabetes April 2005 Phase 4
NCT00470262 VA Office of Research and Development Metabolic Syndrome X|Prediabetic State January 2007
NCT02763007 Kun-Ho Yoon|Takeda|The Catholic University of Korea Diabetes Mellitus, Type 2 May 18, 2016 Phase 4
NCT01107717 The University of Texas Health Science Center at San Antonio|American Diabetes Association|Amylin Pharmaceuticals, LLC. Diabetes January 2009
NCT02774343 The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA) Cocaine Use Disorder|Alcohol Use Disorder August 2012 Phase 1|Phase 2
NCT02875821 Yonsei University Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD) April 26, 2016 Phase 4
NCT00269061 GlaxoSmithKline Non-Insulin-Dependent Diabetes Mellitus January 2006 Phase 1
NCT01570660 German Diabetes Center Type 2 Diabetes Mellitus February 2002
NCT00763139 Vanderbilt University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Rheumatoid Arthritis April 2009
NCT01631630 National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC) Alcohol Dependence|Alcohol Drinking|Stress|Alcohol-Related Disorders May 2012 Phase 2
NCT02172235 Boehringer Ingelheim Healthy April 2010 Phase 1
NCT00554853 University of Michigan|National Heart, Lung, and Blood Institute (NHLBI) Rheumatoid Arthritis November 2007 Phase 3
NCT00885352 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus April 15, 2009 Phase 3
NCT03196362 Sun Yat-sen University Type 2 Diabetes Mellitus December 1, 2016 Phase 4
NCT00700856 Italian Society of Diabetology|Associazione Medici Diabetologi (AMD)|Associazione Nazionale Medici Cardiologi Ospedalieri Type 2 Diabetes Mellitus|Cardiovascular Disease September 2008 Phase 4
NCT01183013 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 August 2010 Phase 3
NCT00086502 Merck Sharp & Dohme Corp. Diabetes Mellitus, Type 2 June 2004 Phase 3
NCT00744367 Hoffmann-La Roche Diabetes Mellitus Type 2 October 2008 Phase 3
NCT00145340 Odense University Hospital Polycystic Ovary Syndrome September 2002 Phase 4
NCT02919176 Philip Kern|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky Obese|Metabolic Syndrome September 1, 2016 Early Phase 1
NCT01043029 Hoffmann-La Roche Diabetes Mellitus Type 2 May 2010 Phase 2
NCT00867126 Simmons Cancer Center|National Cancer Institute (NCI) Pancreatic Cancer February 2009 Phase 1
NCT00904046 University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America, Inc. Uric Acid Kidney Stone Disease May 2009
NCT00656851 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) HIV Infections|Cardiovascular Disease|Insulin Resistance|HIV Lipodystrophy|The Metabolic Syndrome September 2005
NCT01006018 Emory University|Merck Sharp & Dohme Corp. Prediabetic State July 2011
NCT00426413 Emory University Ketosis Prone Diabetes|Diabetic Ketoacidosis|Severe Hyperglycemia May 2007
NCT00226330 AstraZeneca Diabetes Mellitus, Type 2 March 2005 Phase 3
NCT00276497 M.V. Hospital for Diabetes|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals Diabetes October 2003 Phase 1
NCT00419484 Dokkyo Medical University Type 2 Diabetes|Hypertension|Dyslipidemia|Diabetic Nephropathy March 2004 Phase 4
NCT00395941 Postgraduate Institute of Medical Education and Research Psoriasis December 2006 Phase 2
NCT01175486 Taipei Veterans General Hospital, Taiwan Diabetes July 2010 Phase 4
NCT00586261 Mayo Clinic Chronic Kidney Disease March 2006
NCT01612858 Tufts Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Lipodystrophy|HIV Infection June 2011 Phase 4
NCT01614301 University of Regensburg|ClinAssess GmbH Advanced Melanoma May 2012 Phase 1|Phase 2
NCT01432405 Baylor College of Medicine Type 2 Diabetes Mellitus June 2007 Phase 4
NCT01895569 University of Pavia|IRCCS Policlinico S. Matteo Type 2 Diabetes Mellitus June 2013 Phase 4
NCT01909141 Cairo University Polycystic Ovary Syndrome|Infertility August 2013 Early Phase 1
NCT02989649 Takeda Diabetes Mellitus, Type 2 December 2016
NCT02341703 Cairo University Polycystic Ovary Syndrome|Infertility February 2015 Early Phase 1
NCT00108615 VA Office of Research and Development Glucose Metabolism Disorders|Diabetes January 2004 Phase 4
NCT00091949 Yale University|National Institute of Neurological Disorders and Stroke (NINDS)|Takeda Pharmaceuticals North America, Inc. Stroke|Myocardial Infarction|Diabetes February 2005 Phase 3
NCT01010243 University of Regensburg|ClinAssess GmbH Multiple Myeloma October 2009 Phase 1|Phase 2
NCT00242177 University of Illinois at Chicago|Takeda Pharmaceuticals North America, Inc. Multiple Sclerosis, Relapsing-Remitting October 2003 Phase 1
NCT01318122 Takeda Type 2 Diabetes Mellitus May 2008 Phase 2|Phase 3
NCT00179400 Albert Einstein College of Medicine, Inc.|Takeda Type 2 Diabetes Mellitus December 2000
NCT01318070 Takeda Type 2 Diabetes Mellitus November 2007 Phase 2|Phase 3
NCT01339143 Korea University Anam Hospital Diabetes Mellitus|Oxidative Stress April 2010 Phase 4
NCT00411892 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 November 29, 2006 Phase 3
NCT00377975 Pennington Biomedical Research Center Obesity January 2003 Phase 2
NCT02767063 Versailles Hospital Leukemia, Myeloid, Chronic-Phase July 2016 Phase 1|Phase 2
NCT00745914 The University of Hong Kong Endstage Renal Disease|Diabetes September 2008
NCT00745225 The University of Hong Kong|Baxter Healthcare Corporation End-stage Renal Disease February 2006 Phase 4
NCT03030300 Qianfoshan Hospital Type2 Diabetes January 2008 Phase 4
NCT00437970 Menzies School of Health Research Diabetes Mellitus, Type 2 April 2008 Phase 4
NCT01289639 VA Office of Research and Development Fatty Liver October 2005
NCT00743327 National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC) Hypogonadism|Metabolic Syndrome|Diabetes|Inflammation October 2008
NCT00427999 Novartis Pharmaceuticals|Novartis Prostate Cancer February 2007 Phase 2
NCT02133118 Medical Research Foundation, The Netherlands Type 2 Diabetes Mellitus January 1998
NCT02365233 The University of Texas Medical Branch, Galveston Type II Diabetes|Nonalcoholic Fatty Liver May 2013 Phase 4
NCT02535832 University of Alabama at Birmingham Rheumatoid Arthritis|Insulin Resistance September 2015 Phase 1
NCT00484198 Daiichi Sankyo Inc. Type 2 Diabetes Mellitus April 2007 Phase 3
NCT00368017 Vanderbilt University Chronic Kidney Disease April 2006 Phase 2
NCT01748994 Pennington Biomedical Research Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Obesity|Metabolic Syndrome February 2011
NCT00229684 AstraZeneca Diabetes Mellitus, Type 2 September 2004 Phase 2
NCT00196989 GlaxoSmithKline Diabetes Mellitus, Type 2 September 2005 Phase 2
NCT00500331 GlaxoSmithKline Diabetes Mellitus, Type 2 January 2007 Phase 2
NCT00736099 Boehringer Ingelheim Diabetes Mellitus, Type 2 August 2008 Phase 3
NCT00839527 GlaxoSmithKline Diabetes Mellitus, Type 2 February 2009 Phase 3
NCT00846716 Shiga University|Kanazawa Medical University|Nagahama Red Cross Hospital|Nagahama City Hospital|Kohka Public Hospital|Second Okamoto General Hospital|Omihachiman COmmunity Medical Center|Yasu Hospital|Toyosato Hospital|Ako City Hospital|Horide Clinic|Kawabata Clinic|Seta Clinic|Shiga Clinic|Osaka University|NTT West Osaka Hospital|Hyogo prefectural Amagasaki Hospital|Tomita Clinic|Sawada Clinic|Social Insurance Shiga Hospital Type 2 Diabetes Mellitus March 2008
NCT01147627 Sun Yat-sen University|Eli Lilly and Company|Amylin Pharmaceuticals, LLC.|Ministry of Health, China Diabetes Mellitus, Type 2|Newly Diagnosed August 2010
NCT01064687 Eli Lilly and Company Diabetes Mellitus, Type 2 February 2010 Phase 3
NCT01911728 Astellas Pharma Europe B.V.|Medivation, Inc.|Astellas Pharma Inc Pharmacokinetics of MDV3100|Castration Resistant Prostate Cancer (CRPC) July 25, 2011 Phase 1
NCT01471808 Sun Yat-sen University Diabetes Mellitus, Type 2 October 2011 Phase 4
NCT00575874 Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Inc. Type 2 Diabetes August 2007 Phase 2
NCT01289119 Takeda Diabetes Mellitus, Type 2 December 2010 Phase 3
NCT00637273 AstraZeneca|Eli Lilly and Company Type 2 Diabetes Mellitus January 2008 Phase 3
NCT00153166 Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI) Arterial Occlusive Disease|Intermittent Claudication|Insulin Resistance January 2004 Phase 2|Phase 3
NCT00780715 University of Dundee Diabetes Mellitus, Type 2 December 2008 Phase 4
NCT02787551 Sanofi Type 2 Diabetes Mellitus July 6, 2016 Phase 3
NCT01026194 Mitsubishi Tanabe Pharma Corporation Type 2 Diabetes Mellitus December 2009 Phase 3
NCT00362440 Beth Israel Deaconess Medical Center|American Diabetes Association HIV Lipodystrophy August 2006 Phase 2
NCT00443755 Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America, Inc.|National Center for Research Resources (NCRR) Type 2 Diabetes|Insulin Resistance|Metabolic Syndrome August 2005 Phase 2
NCT02305069 University of Nottingham|Biotechnology and Biological Sciences Research Council Obesity|Sarcopenia October 2009
NCT01174056 Washington University School of Medicine|Doris Duke Charitable Foundation Lung Inflammation July 2011 Early Phase 1
NCT00155350 National Taiwan University Hospital Coronary Atherosclerosis|Inflammation|Coronary Heart Disease November 2004 Phase 4
NCT00232583 University of Texas Southwestern Medical Center Type 2 Diabetes Mellitus November 2003
NCT01002547 VA Office of Research and Development Nonalcoholic Steatohepatitis June 24, 2010 Phase 4
NCT01076075 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus June 3, 2010 Phase 3
NCT01230749 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Diabetes Mellitus, Type 2 December 2010 Phase 2
NCT00143520 Daiichi Sankyo Inc. Type 2 Diabetes December 2004 Phase 2|Phase 3
NCT00106704 Merck Sharp & Dohme Corp. Diabetes Mellitus, Type 2 March 2005 Phase 3
NCT00843791 Oregon Health and Science University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Obesity|Insulin Resistance February 2009
NCT00926341 Aligarh Muslim University Metabolic Syndrome October 2006 Phase 4
NCT00543959 Merck Sharp & Dohme Corp. Diabetes Mellitus Type 2 June 2006 Phase 2
NCT00308373 Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diabetes Mellitus, Type 2 July 2004
NCT01817400 University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Infertility, Female|Obesity March 2013 Early Phase 1
NCT02142309 Second University of Naples Type 2 Diabetes October 2005 Phase 4
NCT01025765 National Taiwan University Hospital|Schering-Plough|Merck Sharp & Dohme Corp. Chronic Hepatitis C November 2009 Phase 4
NCT00097279 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 August 2004 Phase 3
NCT00459940 University of Aarhus Growth Hormone Deficiency September 2004
NCT02694263 University of Leicester|University Hospital Birmingham Diabetes Mellitus, Type 2 July 2016 Phase 4
NCT02338999 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC) Systemic Lupus Erthematosus December 29, 2014 Phase 1|Phase 2
NCT00280865 AstraZeneca Type 2 Diabetes April 2002 Phase 2
NCT00694759 Oregon Health and Science University Polycystic Ovary Syndrome October 2006
NCT01489943 GlaxoSmithKline Crohn's Disease September 19, 2011 Phase 1
NCT00722917 Takeda Diabetes Mellitus July 2008 Phase 2
NCT00094757 Merck Sharp & Dohme Corp. Diabetes Mellitus, Type 2 October 2004 Phase 3
NCT02653209 NIHR Exeter Clinical Research Facility|University of Exeter|NHS Tayside|University of Dundee|Royal Devon and Exeter NHS Foundation Trust|University of Glasgow|Newcastle University|King's College London Type 2 Diabetes November 1, 2016 Phase 4
NCT01103414 Metabolic Solutions Development Company Type 2 Diabetes September 2010 Phase 2
NCT00571519 Daiichi Sankyo Inc. Type 2 Diabetes Mellitus November 2007 Phase 3
NCT00086515 Merck Sharp & Dohme Corp. Diabetes Mellitus, Type II June 30, 2004 Phase 3
NCT02592317 Aragon Pharmaceuticals, Inc. Prostatic Neoplasms, Castration-Resistant February 2016 Phase 1
NCT00760578 Metabolic Solutions Development Company Type 2 Diabetes Mellitus September 2008 Phase 2
NCT00879970 GlaxoSmithKline|Academic Research Collaborator: Population Health Research Institute / Hamilton Health Diabetes Mellitus, Type 2 May 2009 Phase 4
NCT00203996 University of Chicago|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI) Polycystic Ovary Syndrome|Obstructive Sleep Apnea September 2003 Phase 4
NCT02969798 The University of Texas Health Science Center at San Antonio|American Diabetes Association|AstraZeneca Diabetes Mellitus, Type 2|Impaired Glucose Tolerance (IGT)|Impaired Fasting Glucose (IFG) January 2014
NCT02917629 National Cancer Institute (NCI) Oral Cavity Neoplasm|Oropharyngeal Neoplasm|Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Oropharyngeal Squamous Cell December 27, 2017 Phase 2
NCT01280695 Metabolic Solutions Development Company Diabetes Mellitus, Type 2 February 2011 Phase 2
NCT00315146 Wake Forest University Health Sciences|Takeda Pharmaceuticals North America, Inc. Obesity|Overweight With Indications for Weight Loss April 2006 Phase 4
NCT03109288 National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Multiple Sclerosis July 28, 2017 Phase 1|Phase 2
NCT02236962 Bayside Health|Baker IDI Heart and Diabetes Institute|The Alfred Type 2 Diabetes|Obesity|Cardiovascular Disease April 2012
NCT02473627 Daiichi Sankyo Inc. Healthy May 2015 Phase 1
NCT01028963 ChemoCentryx Type 2 Diabetes Mellitus January 2010 Phase 2
NCT00212290 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Insulin Resistance|Type 2 Diabetes Mellitus November 2002 Phase 4
NCT00290940 Daiichi Sankyo Inc. Diabetes Mellitus, Type 2 January 2006 Phase 2
NCT02292290 University of Leicester|University Hospitals, Leicester|University Hospital Birmingham Type 2 Diabetes April 2011 Phase 4
NCT01217073 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus October 8, 2010 Phase 2
NCT00121667 AstraZeneca Diabetes Mellitus, Type 2 August 2005 Phase 3
NCT00327015 AstraZeneca Diabetes May 2006 Phase 3
NCT02879409 Weill Cornell Medical College in Qatar|Hamad Medical Corporation|Sidra Medical and Research Center|University of Hull Diabetes Mellitus Type 2 November 2016
NCT00676338 AstraZeneca|Eli Lilly and Company Type 2 Diabetes Mellitus November 2008 Phase 3
NCT00295633 AstraZeneca Diabetes Mellitus, Type 2 March 2006 Phase 3
NCT00680745 AstraZeneca|Bristol-Myers Squibb Type 2 Diabetes April 2008 Phase 3
NCT00683878 AstraZeneca|Astra Zeneca, Bristol-Myers Squibb Type 2 Diabetes July 2008 Phase 3
NCT02072096 Eli Lilly and Company Diabetes Mellitus, Type 2 February 2014 Phase 4
NCT00015626 National Center for Research Resources (NCRR) Insulin Resistance|Diabetes Mellitus Phase 2
NCT01095666 AstraZeneca Type 2 Diabetes June 2010 Phase 3
NCT00673309 The University of Texas Medical Branch, Galveston|National Institutes of Health (NIH) Burns July 2002 Phase 2|Phase 3
NCT00598793 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 November 2002 Phase 3
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.5452 mL 12.7259 mL 25.4518 mL
5 mM 0.5090 mL 2.5452 mL 5.0904 mL
10 mM 0.2545 mL 1.2726 mL 2.5452 mL
Cell Assay
[2]

In order to evaluate cell proliferation, HIT-T15 cells are seeded on 96-well plates (3×104 cells/well) and cultured for 5 days as described. Viable cells are determined using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. To evaluate cell apoptosis and cell necrosis, HIT-T15 cells are plated on 6-well dishes (7×105 cells/well) for 5 days in standard conditions (CTR) or in the presence of AGEs (AGEs) with or without Pioglitazone (0.5 or 1 μM) or AG (1 mM). They are then processed to measure both the activity of caspase-3 and the activity of lactate dehydrogenase (LDH) (a stable cytosolic enzyme that is a marker of cell membrane damage and cell death due to necrosis) using Cytotox 96 Non Radioactive Cytotoxicity Assay[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3][4]

Pioglitazone (AD 4833) hydrochloride is prepared in 0.25% carboxymethylcellulose (Mice)[3].
Pioglitazone hydrochloride is suspended in 0.5% carboxy methyl cellulose (Rat)[4].

Mice[3]
10 mg/kg Pioglitazone HCl or vehicle (0.25% carboxymethylcellulose) is adnimistered to ob/ob and adipo-/- ob/ob mice by oral gavage once daily for 14 consecutive days. 30 mg/kg Pioglitazone or vehicle is also adnimistered to ob/ob and adipo-/- ob/ob mice by oral gavage once daily for 14 consecutive days.
Rat[4]
Male Wistar albino rats (weighing 250±20 g) are ued.Rats that achieved serum glucose level ≥250 mg/dL and serum creatinine level ≥1.5 mg/dL are divided into 2 groups (n=10 per each group): diabetic nephropathic (DN) group in which rats received an equal amount of vehicle (0.5% carboxy methyl cellulose) and Pioglitazone-treated (DN+Pio) group in which rats treated with Pioglitazone. Pioglitazone (10 mg/kg BW) is given orally by gastric gavage, once daily, for 4 weeks. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

392.9

Formula

C₁₉H₂₁ClN₂O₃S

CAS No.

112529-15-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Pioglitazone hydrochloride
Cat. No.:
HY-14601
Quantity: